🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
ALK-Abelló A/S (CPH:ALK.B)
Denmark flag Denmark · Delayed Price · Currency is DKK
242.80
-2.20 (-0.90%)
Nov 20, 2026, 11:21 AM CET
← View all transcripts

Earnings Call: Q3 2026

Nov 17, 2026

Summary

Q3 revenue grew 15% in local currencies, led by tablets, while 9M EBIT margin held at 28%. FY guidance was reaffirmed, with growth investment, China trial progress and expanded tablet capacity supporting the outlook.

Per Plotnikof
Head of Investor Relations, ALK-Abelló

Hello, everyone, and welcome to this presentation of ALK's Q3 and nine months results. Thank you all for joining us. Let's turn to slide two with an introduction to the speakers and the agenda. My name is Per Plotnikof, I am Head of Investor Relations, and with me are CEO Peter Halling and CFO Claus Steensen Sølje. Peter and Claus will walk you through the quarterly highlights, markets, product trends, and the nine months financials. After a brief strategy update, we will turn to the full-year outlook, and as usual, we will end the call with a Q&A session. First, I will hand over to Peter for the highlights on slide three. Please go ahead, Peter.

Peter Halling
CEO, ALK-Abelló

Thank you, Per, and thank you all for taking the time to listen to this call. ALK delivered 15% revenue growth in Q3, measured in local currencies, with growth across all regions. Revenue was DKK 1.76 billion, and the growth was driven by tablets, which were up 35% to DKK 999 million, close to the DKK 1 billion mark we have seen over the last quarters. Operating profit, EBIT, increased by 9% to DKK 469 million. The EBIT margin was 27% compared to 28% last year, and for the first nine months, the margin was 28%, unchanged from last year. In general, we have seen important developments across our business since our last call. Let me provide a few highlights. The pediatric rollout increasingly becomes an important contributor to the tablet growth.

The pediatric launches were an important factor behind the stronger-than-expected tablet sales in Europe and Canada in Q3, and the key performance indicators remain strong. Claus will shortly take you through the regional details. China is the country with the highest number of people with house dust mite allergy, an estimated 100 million people, and fewer than 1 million currently receive allergy immunotherapy. The commercial potential is obviously considerable. Therefore, we were very pleased when we, in October, could announce that the phase III trial with ACARIZAX in China met its primary objective, with efficacy and safety consistent with more than 10 years of clinical data. Together with GenSci, we are now working on filing for regulatory approval, which we plan to submit as soon as possible in 2027. I will come back to this on slide seven. Concerning neffy, or EURneffy, in Europe, the commercialization continues.

Revenue contribution is still modest, but direct sales in Europe and Canada increased approximately sixfold in Q3. The launch in Canada and the launch of the 1 mg version in Germany looks promising. We also signed a partnership with Zuellig Pharma to bring neffy to select Southeast Asian markets. in September, we announced an expanded partnership with Catalent, which provides us with strategic supply robustness. It also secures long-term access to Zydis tablet technology for all our allergen products and lifts our prioritized tablet capacity by 40%. This expanded partnership facilitates the long-term growth which we are planning for ALK. In food allergy, we are advancing our preparations to initiate the pivotal phase III trial with our peanut tablet before the end of the year. Finally, on October 7th, we upgraded our full-year outlook on the back of the strong tablet momentum, and today we confirm that outlook.

Overall, Q3 was a good quarter for ALK, with financial and strategic progress. I will now hand it over to you, Claus, for the regional trends on slide four.

Claus Steensen Sølje
CFO, ALK-Abelló

Thanks, Peter. All three sales regions grew in Q3, and Europe continued to lead. Revenue in Europe increased by 18% in local currencies, driven by tablets. Tablet sales were up 33%, mainly reflecting volume growth linked to the inflow of patients during the 2025 and 2026 initiation season. We are still in the beginning of the initiation season for this year, but it looks strong for the tree tablet ITULAZAX and a bit more moderate for the grass tablet GRAZAX. Moreover, throughout the year, we have seen a decent development in new patient initiations with the house dust mite tablet ACARIZAX. The pediatric and adolescence indications are increasingly contributing to growth, and we also see signs of better treatment adherence in this patient segment. All tablet brands grew by double- digits, led by the tree pollen tablet ITULAZAX.

I should point out that reported sales were, to some extent, positively impacted by fluctuations in wholesaler stocking, including advanced stocking ahead of the main initiation season here in Q4. In Germany, Europe's largest allergy immunotherapy market, tablet sales grew significantly. Growth was also strong in most Central and Eastern European countries, and the U.K. delivered high growth, although from a lower base. As you know, Germany's mandatory rebate increase takes effect from 1st of January 2027, and we are executing an internal action plan to mitigate the impact from this. Combined sales of injection-based SCIT and drop-based treatment increased by 3%. SCIT grew slightly, while SLIT drops sales were flat. The underlying growth continues to be impacted by fewer patients starting SCIT and SLIT drops treatments in favor of the tablets. Sales of anaphylaxis and other products in Europe decreased by 1% to DKK 111 million.

This reflects an exceptional performance in Q3 last year, linked to Jext market share gains and tender wins across the region. In addition to that, the U.K. had a significant higher level of Jext expiries in Q3 last year, which benefited refill sales back then. Sales of EURneffy increased by approximately 250% in this quarter, mainly in Germany, but sales remained modest as the product is still in an early launch phase, with market access processes ongoing in many of the markets. Revenue in North America increased by 8% in local currencies to DKK 270 million. Tablet sales grew by 32%, mostly driven by Canada, which continues to see sustained high growth, helped by the pediatric rollout. The U.S.A. also saw double-digit growth, supported by increased promotional efforts. Sales of SCIT bulk allergens extract, primarily to U.S. allergists, were flat, as slightly lower volumes were offset by higher prices.

Anaphylaxis and other products grew by 2% and benefited from the first sales of neffy in Canada. Sales of other products were impacted by certain PRE-PEN back orders, which we expect to clear later this year. In international markets, revenue grew by 6% in local currencies to DKK 248 million. This reflected a step-up in tablet shipments to Japan, where in-market sales growth is accelerating, particularly of the CEDARCURE tablet, driven by stronger supply of active pharmaceutical ingredients from Torii's new manufacturing facility. Tablet revenue in the region increased by 47% following product shipments and sales royalties from Japan, and growth in most of the minor market in Southeast Asia. Sales of SCIT and SLIT drops were DKK 47 million against an extraordinary high level of SCIT shipments to China in Q3 last year on the back of our renewal of the import licenses we got there.

In China, GenSci's commercialization of our SCIT products and skin prick test continued to progress. The partner transition had temporarily impacted in-market sales, although growths have improved recently. Now, let's continue to slide number five with the product lines. Global tablet sales grew by 35% to DKK 999 million, or 57% of group revenue. That is essentially in line with the level of around DKK 1 billion we saw in Q1 and Q2, and the growth was increasingly driven by pediatric rollout. Europe reported 33% growth in tablet sales, while growth was 32% in North America and 47% in international markets. Combined SCIT and SLIT drop sales decreased by 6% to DKK 527 million, which is 30% of revenue. The decline was due to normalized shipments to international markets, as I just mentioned before. Sales of anaphylaxis and other products increased by 1% to DKK 238 million, or 13% of revenue.

Direct sales of neffy grew sixfold, although from a low base, reflecting the early stage of market introductions, while reimbursement processes still pending in many markets. Now, let's turn to slide six and the financials. For the nine months, revenue increased by 17% in local currencies to DKK 5.3 billion, driven by tablets, anaphylaxis, and SCIT products. Exchange rate impacted reported revenue growth negatively by 1 percentage point, mainly because of the weaker U.S. dollar. Gross profit was DKK 3.6 billion, which yield a gross margin of 68%, up from 67% last year. This was driven by higher sales volumes, production efficiencies, and a sales mix with a relatively higher proportion of ALK's direct sales of products with high margin versus partner sales with lower gross margins. Capacity cost increased by 20% in local currencies to DKK 2.1 billion, following significantly gross investments.

R&D expenses were up 24% to DKK 516 million, mainly reflecting the peanut tablet clinical development and the preclinical projects. Sales and marketing expenses were DKK 1.3 billion, up 20%, driven by the efforts to support the launches of pediatric tablets and neffy, including additional sales resources and dedicated marketing campaigns. Administrative costs increased by 18% to DKK 301 million as a result of scaling up the organization, building the growth infrastructure, and generally a very high activity level. It is important for us to highlight that we are not planning for another step-up in cost going forward. Looking ahead to next year, we are planning for a much more moderate increase in our cost base compared to 2026. Looking at operating profit, it improved by 16% in local currencies to almost DKK 1.5 billion.

The EBIT margin was unchanged at 28%. The improved gross margin was offset by a slightly higher capacity cost-to-revenue ratio. Net financial showed a gain of DKK 33 million related to interest income and currency gains. Net profit increased to DKK 1.1 billion. Free cash flow was DKK 1.19 billion, up from DKK 836 million, driven by higher earnings and changes in working capital. In Q3 alone, free cash flow was DKK 303 million, and the net debt- to- EBITDA ratio remained negative at -0.7x. All in all, another quarter with strong growth and a solid financial position. Now, let's continue to slide seven for the execution of the Allergy+ strategy. Over to you, Peter.

Peter Halling
CEO, ALK-Abelló

Thanks, Claus. Let me take you through the Allergy+ progress, starting with the respiratory allergy. The pediatric tablet rollout continues to boost the inflow of new patients and to expand the prescriber network. By the end of Q3, the house dust mite tablet was approved for pediatric use in 36 countries and launched in 24 of these, with France being the most recent addition. The tree pollen tablet, ITULAZAX, was approved for children and adolescents in 20 countries and launched in 14. Key performance indicators remain strong, including patients initiated, endorsements from key opinion leaders, caregivers, interaction with caregivers, and doctor visits. In China, as I said earlier on, the ACARIZAX phase III trial successfully met its primary objectives. The treatment difference favored ACARIZAX over placebo with a relative difference of 19.1%. The trial was well executed with high treatment compliance.

We'll now work with GenSci to file for approval, with filing expected as soon as possible in the first half of 2027. Subject to approval, a launch could potentially take place towards the end of 2028, and ACARIZAX will be added to GenSci's portfolio. We are very happy with these results, and we see a highly committed partner, so this bodes well for our future in China. To support long-term tablet growth, we have expanded our partnership with Catalent. The agreement secures access to Zydis technology for all our allergen products and increases our prioritized tablet capacity by 300 million tablets, or around 40%, to 1.1 billion tablets annually from the early 2030s, based on sites in the U.K. and in Canada. We will make payments of approximately DKK 500 million over three years, which are capitalized on the balance sheet and amortized over the contract. Turning to anaphylaxis.

At the end of September, the 2 mg version of neffy for adults and children weighing 30 kg or more was launched in 14 markets, and the 1 mg version for children was launched in Germany. Initial feedback on 1 mg version is encouraging in Germany. The 2 mg neffy version was launched in Canada late July and gained good coverage and traction amongst healthcare providers, prescribers, and patients. Canada and Germany were the main contributors to revenue in the quarter, and we still expect these markets to lead the long-term growth together with the U.K. Recently, the Canadian pharmacy regulators classified neffy as Schedule II product across Canada, which means that it will be available without a prescription in areas where a prescription was previously required. In the U.K., formulary access continues to progress, although slowly, reflecting the ongoing healthcare reform and administrative processes in the U.K.

We have recently partnered with Zuellig Pharma in Asia Pacific to bring neffy to select markets in Southeast Asia, including Singapore, Thailand, the Philippines, Malaysia, Indonesia, and Vietnam. Zuellig will sub-license neffy from ALK, and subject to regulatory approval, neffy could become available in these markets within a few years. Finally, let me turn to food allergy and our new disease areas. Preparations are progressing for the pivotal phase III trial with our peanut tablet. We have submitted the clinical trial application, CTA, to U.S. FDA, and we are currently awaiting their feedback on this before we can initiate the trial. Our biologic candidate, ALK-014, targeting the IgE axis of the immune system, continues to progress towards clinical development in 2027.

Finally, the interim data from the phase II-B trial of neffy in acute flares of chronic spontaneous urticaria, or CSU, is still expected in the first quarter of 2027. Our agreement with ARS Pharma gives us exclusive rights to neffy in this and other new indications in the licensed territory. With that update, I'll hand it back over to you, Claus, and the full-year outlook on slide eight.

Claus Steensen Sølje
CFO, ALK-Abelló

Thank you, Peter. On the 7th of October, we upgraded the full-year outlook, reflecting the strong growth momentum in tablet sales across regions. Today, we confirm that outlook. We expect revenue to grow by 16%-17% in local currencies, up from the previous 14%-16%, based on growth across all sales regions and product lines, with tablet as the key driver. The EBIT margin is expected at around 27%, up from 26%, mainly reflecting operating leverage from the higher revenue outlook. Growth will predominantly be volume-driven. Tablet sales are expected to grow by a double digit across regions, with children and adolescents projected to account for a higher share of sales. Combined SCIT and SLIT drop sales are anticipated to grow by single- digits, and anaphylaxis and other products are projected to increase by low- double- digits, with a modest contribution from neffy.

Gross margin is expected to be slightly higher than last year's 67%. The margin will benefit from favorable volume and mix changes, especially higher tablet sales in Europe, partly offset by growth in lower margin partner-related revenue in the remainder of the year, primary shipments to Japan and China, as well as neffy sales. Capacity costs are still projected to increase, and their ratio to revenue is expected to be largely on par with that of last year, as we reinvest the benefits of scale into key growth opportunities and R&D. R&D is expected to slightly exceed 10% of revenue. CapEx is projected at around DKK 400 million, and free cash flow is now expected to exceed DKK 1.1 billion. To sum up, the momentum in the business is strong.

We are in a favorable position to continuously deliver more than 10% growth in the years ahead, while also generating attractive shareholder returns. With this, I would like to hand it back to you, Per, and slide nine.

Per Plotnikof
Head of Investor Relations, ALK-Abelló

Thank you, Claus, and thank you, Peter. This concludes our presentation, and we will now open up the Q&A session. I kindly ask the operator to go ahead, please.

Operator

Thank you. If you'd like to ask a question, please press star then one. To remove yourself from queue, please press star then two. Today's first question comes from Jesper Ingildsen with DNB Carnegie. Please go ahead.

Jesper Ingildsen
Analyst, DNB Carnegie

Yeah. Hi. Thanks so much for taking my questions. I have three, and I'll do one at a time if that's okay. Maybe first if we start out on the strong European tablet growth you saw in the quarter, 33%. Just trying to understand sort of the underlying drivers here in Q3 and also heading into Q4 and then next year. You mentioned the wholesale stocking effect. Could you give any indication to how much that was in the quarter and whether we should expect this to reverse into Q4? In the context of the growth in Europe, you mentioned children. The children launch continued to be a strong driver for the strong growth. I believe in Q2, you mentioned that new patients of new children was driving about 30% of the scripts in the quarter, whilst against your ambition of 50%.

Could you give us an update on that. Lastly, in terms of the tablet growth, could you elaborate a bit if there was any benefit here in Q3 from the initiation season, and more specifically, what you've seen here initially on the initiation season. I believe last year at this point in time, you talked about +10%, well above 10% growth in new patient starts for the tablets in Europe. That will be my question on tablets. Then I will come back with two more questions after.

Peter Halling
CEO, ALK-Abelló

Thank you, Jesper. Three questions, but question 1A, I will hand it over to Claus on the European tablet growth, and I will cover question 1B and 1C.

Claus Steensen Sølje
CFO, ALK-Abelló

Yeah. Thank you, Jesper. Let us see if we can figure this one out. Peter, he will cover part of this, and I will just add this with the wholesaler stocking, as you alluded to. It is right that when Peter is coming back and is talking about the initiation season, then he can add where we see that, but we are expecting a quite nice initiation season, and that also means that we have actually seen some wholesaler stocking here in Q3 on many of our wholesalers across Europe that are kind of ready for the Q4 initiation season. To put some numbers on, then what you can kind of count with is around DKK 20 million-DKK 30 million. But it is important to say there is a lot of fluctuations.

This quarter, that was the same last year, if you recall. So it is difficult to put a precise number on.

But use around DKK 20 million-DKK 30 million that you have seen here that is a stock buildup that probably would belong to Q4. Then I will leave it to Peter for the initiation season.

Peter Halling
CEO, ALK-Abelló

Yeah, we can start. The first question, Jesper, or the second question on children, it continues to be a driver of the business. You are right. We talked about the 30%. We are seeing that continuing and also increasing positively. We are not sharing the numbers, but the long-term goal of 50% remains, and it is really good to see that the launches are supporting that goal. All in all, positive on the children and also above the 30% threshold towards the 50%. On the tablet initiation season, maybe splitting it out, I think if we start out with GRAZAX, it has been fair and at a reasonable level so far as what we would call more of a normal season on that level. We have seen a very solid tree initiation season, particularly pertaining to birch and other relevant tree source for ITULAZAX. That is also a positive driver.

The house dust mite continues, but as you know, that is more a year-round thing for us. Maybe just on that, all in all, on the tablets, I think we are continuing to see good progress across the board. Question two. Jesper?

Jesper Ingildsen
Analyst, DNB Carnegie

Yeah, sorry. Question two would be on Germany. You highlight again that you are executing an internal action plan to mitigate the mandatory rebate increase from 1st of January. You have previously talked about this. Could you give us an update? There was also early October talks about some potential exemptions here around having some of your production or patients located in Germany. Any update on that specifically?

Peter Halling
CEO, ALK-Abelló

Yeah. Thanks, Jesper. It is Peter. I think at best we can say the political environment in Germany remains opaque. It is not 100% clear. There is still, and we are looking into what are basically the options we have in Germany. There is a lot of speculation in terms of how it comes out and what is possible from a legal and also EU regulatory standpoint. So, I would argue that it remains to be seen. We still believe that what we can control and is obviously both the cost side, but also certainly the interaction with the insurers, and that we continue to work on, and that is progressing as planned. In other words, we are basically planning with having the full rebate in our numbers, and then we have upside from there on.

But we still hope and we continue to work on the options there, but it is not clear at this stage what is going to go into law. I know it is a vague answer, but the best I can give you at this stage.

Jesper Ingildsen
Analyst, DNB Carnegie

Great. Last question would be on the recent Danish corporate tax reform proposal, which I understand could cut the rate from 22% to 19%. Just wonder what that would have of implications for you guys. Your current sort of effective tax rate is closer to 24%- 25%. Just wondering sort of how much of your profit is currently taxed in Denmark, and then, yeah, how low your effective tax rate effectively could come on the back of this.

Peter Halling
CEO, ALK-Abelló

Yeah. Claus?

Claus Steensen Sølje
CFO, ALK-Abelló

Yeah. Thanks, Jesper. You are right that if this is, of course, now they have to actually get it through parliament, but in general, of course, it is positive to see that politicians are supporting the business environment and it will, of course, also help with the investments, especially in Denmark. We are actually in a situation where a lot of our profit for many of our therapy areas is actually in Denmark and is taxed in Denmark. So, it actually also means that it has a quite nice impact on our effective tax rate. When we are calculating it right now, and you are right, we are there around 24%-25%, then we are expecting it, when it is fully implemented, that we could go all the way down to around 21% in our effective tax rate.

Now we would have to see when it is implemented and how it is going to be and all the details, but it is going to be a quite significant positive impact that, of course, we believe is good also for Denmark because it gives us an opportunity to continue our investments into ALK.

Jesper Ingildsen
Analyst, DNB Carnegie

Great. Thank you.

Operator

The next question comes from Thomas Bowers with SEB. Please go ahead.

Thomas Bowers
Analyst, SEB

Yes. Thank you very much. I will go with Germany, leaving aside the rebate issue here. It is actually related to the transition away from these unregistered allergen products. You have mentioned earlier that you think it will largely be done with here by year end. I am just wondering how we should think about the implications for 2027. Have most patients already switched to registered product, or is there still a meaningful tailwind that you can gain from that remaining transition going into 2027? My second question, just in regards to ACARIZAX in China here after the positive phase III readout. That regulatory filing, I just want to check here, will that only cover adults?

Have you been in interactions with the authorities in regards to the pediatric indication, whether you can include that or you need another bridging phase III type study to include and broaden the label? Just lastly on Japan, now with SeouLin Bioscience taking over the ACTHAR product here from February 2027. Is there anything you can say here ahead of that February 2027 day? Is there anything that would indicate that we should expect already a positive impact here from early 2027? Thank you.

Peter Halling
CEO, ALK-Abelló

Thank you, Thomas. I will start, and then Per and Claus can jump in on the three questions. Starting with Germany and the TAV. I think the short answer is that transition has been ongoing and is still ongoing. You still see regulatory approvals coming on the tail. We do have competitors who get one or two products in. You also have patients that have been initiated and continues on the products. I would say we still expect impact, but I would say it is less than 10% of the patients that are basically in play here. That being said, we believe we are very well positioned in Germany to win part of that portfolio. We have currently, as you know, a fair market share in Germany that we believe we can continue to progress.

That is obviously a pool of patients that we also remain interested in Germany. In terms of ACARIZAX in China, you are right, this is for adults, and we will have to have a dialogue with the Chinese authorities around how they view it in terms of children. We do not know where they stand, and that would be a discussion actually not facilitated by ALK, but facilitated by our partner, GenSci. I can tell you that both companies will have a very high interest in expanding, so we secure that. There is, at this stage, no clear path in terms of whether we need to do any additional studies or whether the data is sufficient to support it. That would obviously be for discussion.

On Japan, just on Shionogi and the takeover or the divestment of the MA, then we see an extremely strong commitment from Shionogi. They are very keen on progressing in Japan, and we remain confident that this is going to be a very good partnership for both of us. That being said, this obviously goes to competition, but I will say that I think Shionogi, Torii, and ALK jointly have a strong position in Japan, and we expect that there are opportunities in the Japanese market to continue to win share going forward. I think that is the most I can say about that. You are right, we will have to see once the MA is transferred. Did that answer, Thomas?

Thomas Bowers
Analyst, SEB

Yeah, that is great. Thank you very much.

Operator

The next question comes from Sushila Hernandez with Van Lanschot Kempen. Please go ahead.

Speaker 7

Hi, thank you. This is Sandrine on for Sushila. Thank you for taking our questions. A little more on the growth in the tablet sales. Can you shine some light on how you expect the market share to evolve over the next 6 to 12 months? Then maybe a second question on neffy. Could you expand a bit on the launch you are seeing in Canada and Germany, and what is needed for this to be a meaningful contributor to ALK? Thank you.

Peter Halling
CEO, ALK-Abelló

Thank you, Sandrine. I think especially on the second question, could you repeat it? You cut out a bit for us. It was on neffy.

Speaker 7

Yeah. The second question on neffy, just on whether you could expand on the launch in Canada and Germany, and what you think is needed for this to be a meaningful contributor to ALK.

Peter Halling
CEO, ALK-Abelló

I will start out with the market share. As you know, every year, as part of the annual report, we share our view in terms of where we stand in the market. We believe, based on the numbers we have and what we see, that we continue to win market share across most markets. We stand, if we continue as is, also to outperform in terms of the overall market progress globally. I think the answer to your question is, we expect and see opportunities to still win market share. Currently, we are around the 50% mark, plus/minus, but we expect that to continue.

That also tells you that ALK not only have a position where we can grow from our business and expand the markets through prescribers and patients, but actually also that we can win market shares that can be meaningful contributors to our growth going forward. In terms of neffy, then Claus, you want to add a few points?

Claus Steensen Sølje
CFO, ALK-Abelló

Yeah. Thanks, Sandrine, for the question here. If we just start with, Sandrine , Canada and Germany, two important markets here within the whole neffy part. If you look at Canada, then of course, it is still early days. We launched neffy, the two milligram in late July. What we can say is that the start has been quite encouraging, and the coverage and traction among the healthcare providers, prescribers, and patients has actually been very positive. There are three things that we are looking at and that we follow and that we remain positive about. The first one is access. We actually see reimbursement is, of course, still being built, but we have strong patient support programs to support the access and cost barrier. We see this as a positive thing. Second, that is the engagement part.

We have very strong support from healthcare professionals and also patients, and we have had that from day one. There's a lot of support across the country and high engagement. Then thirdly, the whole pharmacy route, as Peter talked about during when we started the session here, that's going to be interesting. The new Schedule II classification, that means that where we had prescription that was required before, then it's now possible to go without one and have your further When you're going to the pharmacy and actually pick up your second neffy, then you actually don't need to get a new prescription. That's a new thing, and that's something that we believe is going to be very positive. In general, in Canada, we see it as a very positive start, but of course, now we need to see the data coming in.

But right now, we see it as positive. If I look at Germany, then it's the 1 mg we have now launched, and we're actually quite comfortable with what we have been seeing there. The 1 mg is especially linked to children. Again, here we can conclude that the whole allergy space and also the anaphylaxis for children is one that is very important. Here we also see a positive development, even again, of course, it's early days. Quite positive with these two concrete things. If this is going to materialize as we are expecting, and also in the other markets across, especially Europe for neffy, then we should start to see next year a contribution from neffy to the numbers, and you will be able to see it in those.

Peter Halling
CEO, ALK-Abelló

I hope that gave an impression on the neffy part.

Speaker 7

That was great. Thank you so much.

Operator

The next question comes from Peter Hugreffe with Nordea. Please go ahead.

Peter Hugreffe
Analyst, Nordea

Yeah, good afternoon. Peter Hugreffe from Nordea. Thank you so much for taking my questions. Claus, this is for you, just to understand what you were saying in terms of the cost base for 2027. I heard something along the lines of a modest cost increase. Can you just help us with the underlying elements of this? Because at least last time I checked, you guys were expecting to grow the R&D in particular. Just help us understanding that part. Secondly, this might also be for you. Sorry. This might also be for you, Claus, in terms of the cash position. Now you are at DKK 1.5 billion, and I can see that it's very healthy cash flow you have.

I know there's a change, that I sound like a broken record, but can you just help me understand what your thinking is in terms of when is enough enough? You heard that before. Just as a sidebar to that one, I think you guided for DKK 1.1 billion for this year, and you are at DKK 1.2 billion. So how should I think about that? Then just finally on peanut, what is in the CTA in terms of drug design, trial design, sorry. Could you share any light on that? That would be appreciated. Thank you.

Peter Halling
CEO, ALK-Abelló

Thank you, Peter. I think, Claus, you're on.

Claus Steensen Sølje
CFO, ALK-Abelló

I'm on for the first two ones. Thanks, Peter. Yes, let me try to clarify a bit on the cost side there. Basically, what we are saying is that after some years where we had, and you have, of course, followed that, our basically quite low investment rate, somewhere around an average of 4%-5% increase in our cost base year-on-year, also to reach the 25% EBIT margin in 2025. Then there's no doubt that 2026 has been a year where we have increased our investments, both within the commercial space, within the R&D, but also within the administrative costs, so especially building infrastructure, scaling the company, and so on. That's why that you have been seeing these around 20% capacity increase in our cost here in the first nine months, and you will also see a quite significant increase in Q4.

What I'm meaning then when I'm looking ahead is just that don't expect next year that we continue to the same tune of percentage increase. We have taken a step up here in 2026, and we will still see an increase in capacity cost next year, but not to the same extent as we have been seeing here this year with the around 20%. So it's just that we try to send a signal, don't expect two years with a 20% increase in capacity cost in a row. That was what I would like to say with that one. That doesn't mean that we are not still seeing an increase in the capacity cost . We are still investing into both the commercial and, of course, especially at R&D with the peanut next year.

If I'm going to touch upon the cash position, you are very welcome to sound like a broken record. It's fair that you do it. You are right, we are building up cash. We know that, and we are in a good situation where we are sitting, especially with this. We will continue to look into different opportunities within the BD part, and we have, of course, still our same policy, invest into the organic growth. We have also now invested into the Catalent expansion that Peter talked about, and we are also looking into the BD&L opportunities still. As we said in August, we will continue to explore those business development opportunities across the different therapy areas. But we are also looking into if this is not going to materialize, what will we then do with the cash?

We plan to come with a plan for that, and that will probably be better later around the full- year announcement. This is what we expected to do there.

Peter Halling
CEO, ALK-Abelló

Good. Then maybe on China CTA, Per, do you want to add a few words?

Per Plotnikof
Head of Investor Relations, ALK-Abelló

On the peanut in the U.S., yes, I mean, there is not much we can say at this stage, Peter. So we have, based on our end of phase II discussions with the authorities, we have implemented their feedback and then submitted the CTA, and now we are waiting for the feedback on that, and then we can get going. So once we have that feedback, we can also share the details of the study design with you. It builds, of course, on the phase II, but until we have the feedback, we need to understand whether everybody is fully aligned with that and when we can be transparent about how it looks. But super exciting, and we look forward to share that with you, hopefully within the next few weeks before Christmas.

Peter Halling
CEO, ALK-Abelló

Yeah. Just to be clear, I said China, I meant peanut. Just to be absolutely clear. Yeah. Thank you.

Peter Hugreffe
Analyst, Nordea

Chinese Peanuts. Thank you. Thank you so much. Much appreciated.

Operator

The next question comes from Håkon Hemme with Danske Bank. Please go ahead.

Håkon Hemme Bro-Jørgensen
Analyst, Danske Bank

Great. Thank you for taking my questions. I have two, please. First on the pediatric launches. Back in Q1, you highlighted more than 4,000 pediatric prescribers and around 4,500 in Q2, but you haven't been updated these numbers in this Q3 report. Could you update that number for us? I was just wondering whether the prescriber recruitment is starting to plateau with growth increasingly coming from more patients per the network. Then on anaphylaxis, where performance now appears to be more normalizing after last year's strong market share gains for Jext. How would you describe the competitive intensity in the adrenaline market today, both for Jext and EURneffy? Are you seeing any changes in pricing, tender competition, or prescriber behavior, or anything that affects your ability to retain shares and expand EURneffy adoption? Thank you.

Peter Halling
CEO, ALK-Abelló

Thank you. I think I can jump on both here. We've decided that on the pediatric part, in terms of actually measuring the amount of new prescribers, et cetera, as we expand, it becomes more difficult. But bottom line is, we are adding. I think that's a positive. As we expand into new markets, and even in existing ones, we see a continued progress on this. I think we feel more comfortable talking about specific numbers when we've kind of been through the annual discussions with our commercial excellence teams, et cetera. But the short answer is, Håkon, that we continue to see progress. And obviously, in new markets, it's even higher than what we see in the existing ones. So, that's a positive. On the anaphylaxis, do remember, there's a couple of different things.

Firstly, when we look at the markets, we have to divide into the tender business, which is a highly competitive business, but for one category of products, the auto-injectors, that's mainly in Northern Europe, but also parts of Italy, et cetera, where you have that tender business. That is a business we participated in for many, many years. In France, Spain, U.K., other markets, actually, the prices are set across, and there you have ongoing negotiations, but you also have price discussions with the governments. What is interesting is that in some of these markets, we're actually seeing price increases in the past years that has helped us, and that continues. And that has to do with supply and demand. Yes, it's a highly competitive market. It has a lot to do with supply, and also some of the supply disruptions that have been going on in the markets.

But I really think where we have gained is that we have stabilized our supply situation. We have a fairly strong supply situation, but we also won some tenders. With the shelf life playing into it, you don't run kind of year-over-year, but actually, in some cases, it's shelf life between 14 and 22 months, when you talk about Jext. That's also what you saw in the U.K., is that some of this is playing into the numbers, and that means that it becomes a little more difficult for us to talk about it quarter-over-quarter, specifically. That is just part of that market. Then neffy. Neffy is a different ballpark. Obviously, there is a competition, you could say, with the existing patients that are on auto-injectors that we are working to convert.

But we are also seeing that neffy plays in with its relevance, both on the shelf life, but certainly also in its ease of use, and its good product capabilities that are relevant to especially younger children, but also adolescents and grown-ups. So, we've really seen neffy playing a strong role in developing the markets, and that is what we also continue to see in some of the other markets. Long story short, existing business on the anaphylaxis with Jext and the auto-injectors is a market that we've seen in the past that continues to be a competitive market. Neffy can play in both that, in the conversion of patients, but also in the market expansion. All in all, it's pretty much as we expected, and we expect that to continue in the coming years.

As we also alluded to, the double-digit growth is certainly something we could also foresee going forward. So, we remain quite positive around the future development of the anaphylaxis portfolio for us. Long answer, but hopefully gave you some clarity.

Håkon Hemme Bro-Jørgensen
Analyst, Danske Bank

That's clear. Thank you.

Operator

This concludes our question- and- answer session. I would like to turn the conference back over to management for any closing remarks.

Per Plotnikof
Head of Investor Relations, ALK-Abelló

Excellent. Thank you all for, as usual, a number of good questions. Before we end the call, let me just draw your attention to a few upcoming investor events. Further to this, we will publish our annual report for 2026 on the 9th of February 2027. With this, we look forward to meet you on the road, and we will end today's session. Have a nice day, all. Thank you. Goodbye.